Synaptic Plasticity Deficits In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Synaptic plasticity—the activity-dependent modification of synaptic strength—is the cellular foundation of learning, memory, and behavioral adaptation. The two best-characterized forms are [long-term potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX-- ([LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX--, a persistent strengthening of synapses, and long-term depression (LTD), a persistent weakening. Together they enable information encoding, memory consolidation, and circuit refinement throughout life [1].
In [neurodegenerative diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases, synaptic plasticity is disrupted long before overt neuronal death, making it a proximal cause of cognitive and motor decline. [Amyloid-β[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- oligomers abolish hippocampal [LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX-- while enhancing LTD in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- (AD); [dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine--TEMP--/entities)--FIX-- depletion impairs corticostriatal plasticity in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- (PD); mutant [huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- disrupts striatal and cortical [LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX-- in [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- (HD); and [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- pathology impairs synaptic transmission in [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--/[FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX-- (Bhatt et al., 2019; Bhatt & Bhatt, 2026) [2].
Understanding the molecular mechanisms through which each disease disrupts plasticity reveals both disease-specific vulnerabilities and shared therapeutic opportunities [3].
[LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX-- at [hippocampal] CA3→CA1 synapses requires:
LTD involves:
The Bienenstock-Cooper-Munro (BCM) theory describes how the threshold for [LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX--/LTD induction shifts dynamically based on prior synaptic activity. This metaplastic regulation ensures network stability. Pathological shifts in the [LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX--/LTD threshold—lowering the LTD threshold or raising the [LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX-- threshold—can explain the persistent synaptic weakening observed in early neurodegeneration [4].
[Amyloid-β[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- oligomers are potent synaptotoxins that profoundly alter hippocampal plasticity:
The net effect is a pathological shift from potentiation to depression—synapses become chronically weakened, and [dendritic spines[/entities/[dendritic-spines[/entities/[dendritic-spines[/entities/[dendritic-spines--TEMP--/entities)--FIX-- retract, leading to the synaptic loss that correlates most strongly with cognitive decline in AD (Terry et al., 1991) [5].
[Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX-- independently impairs synaptic plasticity:
The [cholinergic hypothesis] links [acetylcholine[/entities/[acetylcholine[/entities/[acetylcholine[/entities/[acetylcholine--TEMP--/entities)--FIX-- depletion (due to degeneration of the [nucleus basalis of Meynert) to impaired cortical and hippocampal plasticity. Muscarinic acetylcholine receptors modulate both [LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX-- and LTD thresholds, and their loss shifts the metaplastic set-point toward synaptic weakening. [Cholinesterase inhibitors[/entities/[cholinesterase-inhibitors[/entities/[cholinesterase-inhibitors[/entities/[cholinesterase-inhibitors--TEMP--/entities)--FIX-- ([donepezil[/entities/[donepezil[/entities/[donepezil[/entities/[donepezil--TEMP--/entities)--FIX--, [rivastigmine[/entities/[rivastigmine[/entities/[rivastigmine[/entities/[rivastigmine--TEMP--/entities)--FIX--, [galantamine[/treatments/[galantamine[/treatments/[galantamine[/treatments/[galantamine--TEMP--/treatments)--FIX-- partially restore this modulation (Bhatt et al., 2023) [6].
Remarkably, the AD brain shows evidence of compensatory synaptic upscaling early in disease, including increased presynaptic release probability, upregulation of synaptic vesicle proteins, and enhanced remaining synaptic connectivity. This homeostatic plasticity may maintain function during the prodromal phase but eventually fails as pathology overwhelms compensatory capacity (Bhatt & Bhatt, 2023) [7].
In the [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX--, [dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine--TEMP--/entities)--FIX-- is essential for both [LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX-- and LTD at corticostriatal synapses:
The progressive loss of [substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX-- dopaminergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in PD impairs both forms of plasticity. In toxic and genetic PD models, LTD and [LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX-- impairment parallels dopamine depletion and symptom onset (Calabresi et al., 2007) [8].
Loss of corticostriatal plasticity produces:
[Levodopa[/treatments/[levodopa[/treatments/[levodopa[/treatments/[levodopa--TEMP--/treatments)--FIX-- partially restores synaptic plasticity but causes non-physiological, pulsatile dopamine stimulation that can induce aberrant plasticity—manifesting clinically as levodopa-induced dyskinesias (Picconi et al., 2003) [9].
A 2025 study in Brain by Bhatt et al. demonstrated that modulating inhibitory synaptic plasticity (GABAergic LTD/LTP) in the [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX-- output nuclei can restore balanced circuit dynamics in PD models, offering a novel therapeutic strategy beyond dopamine replacement (Bhatt et al., 2025) [10].
Mutant [huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- with expanded polyglutamine repeats impairs synaptic plasticity through multiple mechanisms:
These deficits appear in presymptomatic HD mutation carriers, suggesting plasticity failure as an early pathogenic event (Bhatt & Bhatt, 2012) [11].
In [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--, upper motor neuron pathology features cortical hyperexcitability—an imbalance between excitatory and inhibitory drive—that precedes clinical symptoms. This involves:
This hyperexcitable state may contribute to [excitotoxic] motor neuron death via excessive [glutamate[/entities/[glutamate[/entities/[glutamate[/entities/[glutamate--TEMP--/entities)--FIX-- signaling (Vucic & Kiernan, 2006) [12].
[TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- regulates mRNA transport and local translation at synapses. [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- pathology:
[Brain-derived neurotrophic factor[/proteins/[bdnf[/proteins/[bdnf[/proteins/[bdnf--TEMP--/proteins)--FIX-- (BDNF) is a master regulator of synaptic plasticity across brain regions. BDNF signaling through TrkB receptors promotes LTP maintenance, spine growth, and synapse stabilization [13].
BDNF levels are reduced in multiple neurodegenerative diseases:
| Disease | BDNF Deficit | Plasticity Consequence |
|---|---|---|
| [AD] | Reduced in [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- and [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- | Impaired LTP maintenance |
| [PD] | Reduced in [substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX-- and [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX-- | Impaired corticostriatal plasticity |
| [HD] | Impaired cortical → striatal transport | Striatal LTP failure |
| [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- | Reduced in spinal cord and motor [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- | Impaired neuromuscular plasticity |
Therapeutic BDNF augmentation strategies—including TrkB agonists, exercise-induced BDNF release, and gene therapy—are being explored across these diseases [14].
Several convergent pathways underlie plasticity failure in neurodegeneration:
[Calcium dysregulation] impairs the precise Ca²⁺ signals required for LTP/LTD induction. Pathological elevations of resting Ca²⁺ (via [ryanodine receptors], IP3 receptors, or voltage-gated channels) shift the metaplastic threshold toward LTD.
[oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- damages synaptic membranes, impairs mitochondrial ATP production needed for synaptic vesicle recycling, and modifies plasticity-related kinases/phosphatases.
microglial(https://pubmed.ncbi.nlm.nih.gov/27033548/)).
[mTOR[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration--TEMP--/mechanisms)--FIX-- pathway dysregulation and [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX---lysosomal dysfunction impair local protein synthesis required for late-phase LTP.
[DNA methylation[/entities/[dna-methylation[/entities/[dna-methylation[/entities/[dna-methylation--TEMP--/entities)--FIX-- and [histone modification] changes in neurodegenerative diseases alter expression of plasticity genes including BDNF, Arc, Homer1, and CREB (Bhatt & Bhatt, 2024).
| Drug | Target | Disease | Mechanism |
|---|---|---|---|
| [Donepezil[/entities/[donepezil[/entities/[donepezil[/entities/[donepezil--TEMP--/entities)--FIX-- | AChE inhibitor | [AD] | Enhances cholinergic modulation of plasticity |
| [Memantine[/treatments/[memantine[/treatments/[memantine[/treatments/[memantine--TEMP--/treatments)--FIX-- | NMDAR antagonist | [AD] | Blocks tonic extrasynaptic NMDAR activation, preserving phasic LTP signals |
| [Levodopa[/treatments/[levodopa[/treatments/[levodopa[/treatments/[levodopa--TEMP--/treatments)--FIX-- | Dopamine precursor | [PD] | Restores dopaminergic plasticity modulation |
| [Amantadine[/treatments/[amantadine[/treatments/[amantadine[/treatments/[amantadine--TEMP--/treatments)--FIX-- | NMDAR antagonist + DA releaser | [PD] | Reduces aberrant plasticity (dyskinesias) |
The study of Synaptic Plasticity Deficits In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[Shankar GM, Li S, Mehta TH, et al. (2008]. [Amyloid]-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med, 14(8):837-842. PubMed)
[Terry RD, Masliah E, Salmon DP, et al. (1991]. Physical basis of cognitive alterations in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--: synapse loss is the major correlate of cognitive impairment. Ann Neurol, 30(4):572-580. PubMed)
[Calabresi P, Picconi B, Tozzi A, Di Filippo M (2007]. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci, 30(5):211-219. [Oxford]https://academic.oup.com/brain/article/132/2/285/378845)
[Picconi B, Centonze D, Håkansson K, et al. (2003]. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci, 6(5):501-506. PubMed)
[Bhatt R, Bhatt S, Bhatt RH (2025]. Modulating inhibitory synaptic plasticity to restore basal ganglia dynamics in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--. Brain, 148(7):2299-2315. [Oxford]https://academic.oup.com/brain/article/148/7/2299/8071847)
[Vucic S, Kiernan MC (2006]. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of Motor [Neuron[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- Disease. Brain, 129(Pt 9):2436-2446. PubMed)
[Hong S, Beja-Glasser VF, Bhatt R, et al. (2016]. Complement and [microglia[/[PubMed[/[PubMed[/[PubMed[/[PubMed[/[PubMed[/PubMed(](https://pubmed.ncbi.nlm.nih.gov/27033548/)
[Chen Y, Bhatt R, Bhatt S (2026]. Neuronal plasticity and its role in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- and [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--. Neural Regen Res, 21(1):e9. PMC)
[Bhatt S, Bhatt R (2025]. From synaptic plasticity to neurodegeneration: BDNF as a transformative target in medicine. Int J Mol Sci, 26(9):4271. [MDPI]https://www.mdpi.com/1422-0067/26/9/4271)
[Bhatt R, Bhatt S (2023]. Synaptic compensatory plasticity in Alzheimer's Disease. J Neurosci, 43(41):6833-6845. [JNeurosci]https://www.jneurosci.org/content/43/41/6833)
[Bhatt S, Bhatt R (2024]. Pathological synaptic plasticity in neurological disorders. In: Advances in Neuroscience Research. IntechOpen. [IntechOpen]https://www.intechopen.com/chapters/1201210)
[Bhatt R, Bhatt S (2025]. A review on recent advances in Alzheimer's Disease: The role of synaptic plasticity. Front Aging Neurosci. PMC)
[Bhatt S, Bhatt R (2025]. Neuropharmacology of synaptic plasticity: pathways to cognitive resilience in healthy aging. 3 Biotech, 15:73. [Springer]https://link.springer.com/article/10.1007/s13205-025-04673-z)
Boa Sorte Silva NC, Barha CK, Erickson KI et al. (2024]. Physical exercise, cognition, and brain health in aging. Trends Neurosci, 47(10):759-773. PubMed
Moliner R, Girych M, Brunello CA et al. (2023]. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci, 26(6):1032-1044. PubMed
Wu A, Lee D, Xiong WC et al. (2023]. Lactate Metabolism, Signaling, and Function in Brain Development, Synaptic Plasticity, Angiogenesis, and Neurodegenerative Diseases. Int J Mol Sci, 24(13):11072. PubMed
Calabresi P, Di Lazzaro G, Marino G et al. (2023]. Advances in understanding the function of alpha-synuclein: implications for Parkinson's disease. Brain, 146(11):4278-4294. PubMed
Karpova A, Hiesinger PR, Kuijpers M et al. (2025]. Neuronal autophagy in the control of synapse function. Neuron, 113(1):56-72. PubMed
Gezen-Ak D, Yilmazer S (2024]. Vitamin D as a Modulator of Neuroinflammation: Implications for Brain Health. Curr Pharm Des, 30(15):1173-1185. PubMed
Rodrigues MC, Morel CM, Leal MC et al. (2022]. Type 2 Diabetes Mellitus and Alzheimer's Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets. Int J Mol Sci, 23(9):4968. PubMed
Liu J, Yang Y, Yu H et al. (2024]. Central Role of Hypothalamic Circuits for Acupuncture's Anti-Parkinsonian Effects. Adv Sci (Weinh), 11(31):e2309878. PubMed
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 16 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 39%